TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Dec, 30, 2022
The analyst comments "TGTX stock is up >15... See more
Dec, 30, 2022
Ignorant analyst are a plus.
HOFV
Hall of Fame Resort & Entertainment Company
-33.20%
$12.62 - $8.43
Feb 7th 2023 - Mar 21st 2023
Jan, 30, 2023
$ATER Excellent - still holding here (and bought s... See more
Jan, 24, 2023
I’m excited for some price bumps from reputable analysts.
AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Dec, 12, 2022
They have occasionally addressed negative concerns... See more
Dec, 3, 2022
The responsible thing for any analyst to do is to ... See more
Dec, 30, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Dec, 30, 2022
Ignorant analyst are a plus.
Dec, 30, 2022
This stock would go far beyond analysts Price Target.
Dec, 30, 2022
$TGTX , absolutely amazing….Scumbag’s Bank of America analyst rated TG today as underperform $6….total joke….I guess the analyst is waiting for FDA approval…LOL ….stick to loans and mortgages….very bullish TG community Longs….
Dec, 29, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Jan, 30, 2023
$ATER Excellent - still holding here (and bought some more) Also $flgc $aemd (love this one) $hofv (Analyst PT of 65)
Jan, 24, 2023
I’m excited for some price bumps from reputable analysts.
Jan, 9, 2023
$HOFV looks like we got a recent strong buy from the analysts on stocksanalysis.com
Jan, 6, 2023
$HOFV I love that the low analyst price target is still a 200% upside.
Dec, 12, 2022
They have occasionally addressed negative concerns raised by some analysts directly (to refute and explain).
Dec, 3, 2022
The responsible thing for any analyst to do is to acknowledge the results appear promising
Nov, 21, 2022
6 out of 6 analysts have a strong buy rating.